Artificial Intelligence and Breast Cancer Management: From Data to the Clinic

Overview

Journal Cancer Innov

Specialty Biomedical Engineering

Date 2025 Feb 21

PMID 39981497

Authors

Kaixiang Feng

Zongbi Yi

Binghe Xu

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) remains a significant threat to women's health worldwide. The oncology field had an exponential growth in the abundance of medical images, clinical information, and genomic data. With its continuous advancement and refinement, artificial intelligence (AI) has demonstrated exceptional capabilities in processing intricate multidimensional BC-related data. AI has proven advantageous in various facets of BC management, encompassing efficient screening and diagnosis, precise prognosis assessment, and personalized treatment planning. However, the implementation of AI into precision medicine and clinical practice presents ongoing challenges that necessitate enhanced regulation, transparency, fairness, and integration of multiple clinical pathways. In this review, we provide a comprehensive overview of the current research related to AI in BC, highlighting its extensive applications throughout the whole BC cycle management and its potential for innovative impact. Furthermore, this article emphasizes the significance of constructing patient-oriented AI algorithms. Additionally, we explore the opportunities and potential research directions within this burgeoning field.

References

Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J . Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91. PMC: 5125250. DOI: 10.1056/NEJMoa1209124. View

Swain S, Shastry M, Hamilton E . Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2022; 22(2):101-126. PMC: 9640784. DOI: 10.1038/s41573-022-00579-0. View

Nolan E, Lindeman G, Visvader J . Deciphering breast cancer: from biology to the clinic. Cell. 2023; 186(8):1708-1728. DOI: 10.1016/j.cell.2023.01.040. View

Shen Y, E Shamout F, Oliver J, Witowski J, Kannan K, Park J . Artificial intelligence system reduces false-positive findings in the interpretation of breast ultrasound exams. Nat Commun. 2021; 12(1):5645. PMC: 8463596. DOI: 10.1038/s41467-021-26023-2. View

Swanson K, Wu E, Zhang A, Alizadeh A, Zou J . From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell. 2023; 186(8):1772-1791. DOI: 10.1016/j.cell.2023.01.035. View

Pfob A, Mehrara B, Nelson J, Wilkins E, Pusic A, Sidey-Gibbons C . Towards Patient-centered Decision-making in Breast Cancer Surgery: Machine Learning to Predict Individual Patient-reported Outcomes at 1-year Follow-up. Ann Surg. 2021; 277(1):e144-e152. PMC: 9762704. DOI: 10.1097/SLA.0000000000004862. View

Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T . Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021; 5(6):586-599. DOI: 10.1038/s41551-021-00746-5. View

You J, Huang Y, Ouyang L, Zhang X, Chen P, Wu X . Automated and reusable deep learning (AutoRDL) framework for predicting response to neoadjuvant chemotherapy and axillary lymph node metastasis in breast cancer using ultrasound images: a retrospective, multicentre study. EClinicalMedicine. 2024; 69:102499. PMC: 10909626. DOI: 10.1016/j.eclinm.2024.102499. View

Callaway E . 'The entire protein universe': AI predicts shape of nearly every known protein. Nature. 2022; 608(7921):15-16. DOI: 10.1038/d41586-022-02083-2. View

10.

Shen J, Choi Y, Lee T, Kim H, Chae Y, Dulken B . Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. J Immunother Cancer. 2024; 12(2). PMC: 10868175. DOI: 10.1136/jitc-2023-008339. View

11.

Fu M, Wang Y, Li C, Qiu Z, Axelrod D, Guth A . Machine learning for detection of lymphedema among breast cancer survivors. Mhealth. 2018; 4:17. PMC: 5994440. DOI: 10.21037/mhealth.2018.04.02. View

12.

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

13.

Leung K, Rowe S, Sadaghiani M, Leal J, Mena E, Choyke P . Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT. J Nucl Med. 2024; 65(4):643-650. PMC: 10995523. DOI: 10.2967/jnumed.123.267048. View

14.

Nguyen L, Van Hoeck A, Cuppen E . Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. Nat Commun. 2022; 13(1):4013. PMC: 9273599. DOI: 10.1038/s41467-022-31666-w. View

15.

Song S, Woo O, Cho Y, Cho K, Park K, Kim J . Prediction of Axillary Lymph Node Metastasis in Early-stage Triple-Negative Breast Cancer Using Multiparametric and Radiomic Features of Breast MRI. Acad Radiol. 2023; 30 Suppl 2:S25-S37. DOI: 10.1016/j.acra.2023.05.025. View

16.

Agostinetto E, Gligorov J, Piccart M . Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol. 2022; 19(12):763-774. PMC: 9575647. DOI: 10.1038/s41571-022-00687-1. View

17.

Li T, Li Y, Zhu X, He Y, Wu Y, Ying T . Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction. Semin Cancer Biol. 2023; 91:50-69. DOI: 10.1016/j.semcancer.2023.02.007. View

18.

Ming C, Viassolo V, Probst-Hensch N, Dinov I, Chappuis P, Katapodi M . Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations. Br J Cancer. 2020; 123(5):860-867. PMC: 7463251. DOI: 10.1038/s41416-020-0937-0. View

19.

Damiani C, Kalliatakis G, Sreenivas M, Al-Attar M, Rose J, Pudney C . Evaluation of an AI Model to Assess Future Breast Cancer Risk. Radiology. 2023; 307(5):e222679. DOI: 10.1148/radiol.222679. View

20.

Park S, Silva E, Singhal A, Kelly M, Licon K, Panagiotou I . A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors. Nat Cancer. 2024; 5(7):996-1009. PMC: 11286358. DOI: 10.1038/s43018-024-00740-1. View